GLP-1 Drugs Oral List: Every Pill That's Approved, Pending, and In Development

Key Takeaways

• Only one oral GLP-1 drug is FDA-approved as of April 2026: Rybelsus (oral semaglutide).
• Rybelsus is approved for type 2 diabetes only, not weight loss, although a higher-dose obesity formulation is under FDA review.
• Orforglipron and danuglipron are non-peptide oral GLP-1 agonists in late-stage trials. Approval expected 2026 to 2027.
• Oral GLP-1 absorption is intentionally low (under 1%) because peptides are digested by the stomach. Strict timing rules apply.
• Oral GLP-1 weight loss is meaningfully lower than injectable counterparts at currently available doses.

Direct answer (40-60 words, snippet-optimized)

The oral GLP-1 list in 2026 is short. Rybelsus (oral semaglutide, 3, 7, and 14 mg) is the only FDA-approved oral GLP-1 medication, indicated for type 2 diabetes. Higher-dose oral semaglutide for obesity, plus orforglipron (Eli Lilly) and danuglipron (Pfizer), are in late-stage trials with approvals expected 2026 to 2027.

Table of contents

1. The 30-second answer
2. The complete oral GLP-1 list, current and pipeline
3. Rybelsus: the only one you can fill today
4. Why oral GLP-1 was so hard to make
5. Orforglipron, danuglipron, and the next generation
6. Oral semaglutide for obesity (Wegovy oral)
7. How oral GLP-1 weight loss compares to injectable
8. Side effects of oral GLP-1
9. The strict timing rules of Rybelsus
10. Cost and insurance coverage in 2026
11. FAQ
12. Footer disclaimers

The complete oral GLP-1 list, current and pipeline

That's the entire list as of early 2026. The story of oral GLP-1 development is short because the chemistry is hard. Most of the entries above are non-peptide small molecules, a different drug class than the injectable peptides like semaglutide and tirzepatide.

Rybelsus: the only one you can fill today

Rybelsus is oral semaglutide. Same active ingredient as Ozempic and Wegovy, but in a tablet instead of a pen. Novo Nordisk solved the absorption problem with a co-formulated absorption enhancer called SNAC (sodium N-(8-[2-hydroxybenzoyl]amino) caprylate).

When you swallow a Rybelsus tablet, SNAC briefly raises the pH right around the tablet, which slows down peptide degradation by stomach acid and pepsin and increases the chance that some semaglutide makes it across the stomach lining and into the bloodstream. The bioavailability is still low, around 0.4 to 1%. To deliver a useful dose, the oral tablet must contain much more semaglutide than the injectable.

Approved doses:

• Rybelsus 3 mg (starting dose, used for one month)
• Rybelsus 7 mg (typical maintenance dose for some patients)
• Rybelsus 14 mg (typical maintenance dose for most patients)

Approved indication: Type 2 diabetes in adults, alone or in combination with other diabetes medications. Not approved for weight loss as a standalone indication, although weight loss is a documented secondary effect.

Average effects (from the PIONEER trial program, Aroda et al., Diabetes Care 2019, and follow-ups):

• A1C reduction of 0.6 to 1.4% depending on dose
• Weight loss of 1 to 4 kg over 26 to 52 weeks at 14 mg
• Cardiovascular safety similar to injectable semaglutide

The drug must be taken at a specific time, with strict water and fasting rules covered in detail below. Adherence to those rules is the most important factor in whether Rybelsus works.

Why oral GLP-1 was so hard to make

Three reasons.

Stomach acid. The pH of the stomach is around 1 to 3, which denatures most peptides. A peptide drug exposed to that environment without protection is broken into amino acid fragments within minutes.

Digestive enzymes. Pepsin in the stomach and a battery of proteases in the small intestine are designed to break peptides into single amino acids for absorption. A peptide drug looks like food to those enzymes.

Membrane permeability. Even if a peptide survives digestion, peptides don't cross intestinal cell membranes well. They're too big and too polar.

Pharmaceutical companies spent decades trying to solve oral peptide delivery for insulin, glucagon, and other peptides. Most attempts failed. Rybelsus was the first commercially successful oral peptide drug for chronic use, and even with SNAC the bioavailability is under 1%.

The next generation (orforglipron, danuglipron) sidesteps the problem entirely. These molecules aren't peptides. They're small molecules engineered to bind the GLP-1 receptor without being shaped like the natural peptide. Small molecules survive the stomach and absorb well, like a typical pill.

Orforglipron, danuglipron, and the next generation

Orforglipron (Eli Lilly). A non-peptide oral GLP-1 receptor agonist. Phase 2 trial (Frias et al., NEJM 2023) showed up to 14.7% weight loss at 36 weeks in patients with obesity, with A1C reductions of 2.1% in patients with type 2 diabetes. Phase 3 (ATTAIN program) is reading out in 2026. Eli Lilly has signaled FDA filing in 2026 if Phase 3 confirms the Phase 2 numbers.

Danuglipron (Pfizer). Another non-peptide oral GLP-1 agonist. Phase 2 trial (Saxena et al., JAMA Network Open 2023) showed about 11% placebo-adjusted weight loss at 32 weeks. Pfizer originally planned twice-daily dosing, paused the original Phase 3 program in 2023 to develop a once-daily modified-release formulation, and is now expected to refile Phase 3 in 2026 to 2027.

Lotiglipron (Pfizer, discontinued). Pfizer's earlier candidate showed elevated liver enzymes in Phase 2 and was halted in 2023. Replaced internally by danuglipron.

GSBR-1290 (Structure Therapeutics). Phase 2b in progress as of early 2026. Early data shows weight loss similar to orforglipron with potentially better gastrointestinal tolerability.

These molecules don't bind the GLP-1 receptor in exactly the same place as natural GLP-1 or semaglutide. They activate the same downstream signaling but through what biochemists call an allosteric mechanism. The clinical effect is similar (appetite suppression, slowed gastric emptying, insulin response). The molecule itself is fundamentally different.

If approved, orforglipron and similar drugs could meaningfully change the GLP-1 market. A daily pill is more acceptable to many patients than a weekly injection, and small molecules are usually cheaper to manufacture than peptides.

Oral semaglutide for obesity (Wegovy oral)

In late 2023, Novo Nordisk reported Phase 3 data for high-dose oral semaglutide (25 mg and 50 mg) for obesity. The OASIS-1 trial (Knop et al., Lancet 2023) showed:

• Mean weight loss of 15.1% at 50 mg over 68 weeks
• Mean weight loss of 11.4% at 25 mg
• Comparable safety to injectable semaglutide

The 50 mg oral dose roughly matches the weight loss of injectable Wegovy 2.4 mg. The trade-off is much higher daily oral dose to overcome the under-1% bioavailability.

FDA review of high-dose oral semaglutide for obesity is in progress. Novo Nordisk has not publicly committed to a brand name. Some commentators refer to it informally as "oral Wegovy." If approved, it would be the second oral GLP-1 in the U.S. market.

Pricing is expected to be similar to injectable Wegovy, in the $1,000 to $1,400 per month range without insurance. Insurance coverage will follow the same prior authorization patterns as the injectable.

How oral GLP-1 weight loss compares to injectable

A direct comparison at currently approved doses:

The takeaway: at currently approved doses, oral Rybelsus is meaningfully less effective for weight loss than injectable Wegovy or Zepbound. The pipeline drugs (high-dose oral semaglutide, orforglipron) close that gap, but they're not approved yet.

For a patient prioritizing maximum weight loss in 2026, the injectable forms remain the more effective option. For a patient who can't or won't inject, Rybelsus is the only oral option, and its weight loss effect is real but smaller.

Side effects of oral GLP-1

Side effects of Rybelsus closely match injectable semaglutide:

• Nausea (10 to 20%), often during the first 4 to 8 weeks of titration
• Diarrhea or constipation (5 to 10%)
• Vomiting (5 to 7%)
• Decreased appetite (often the desired effect, but uncomfortable)
• Fatigue
• Headache

Rare but serious:

• Pancreatitis (about 0.3% per year of use across the GLP-1 class)
• Gallstones during rapid weight loss
• Acute kidney injury, usually secondary to severe vomiting and dehydration
• Possible thyroid C-cell tumors (rodent data; human signal unclear)

The black-box warning for medullary thyroid carcinoma applies to all semaglutide products including Rybelsus.

Pipeline non-peptide oral GLP-1 drugs (orforglipron, danuglipron) show similar gastrointestinal side effects in trials. Lotiglipron's discontinuation due to liver enzyme elevations is a reminder that small-molecule GLP-1 agonists may have unique safety profiles distinct from the peptide class.

The strict timing rules of Rybelsus

Rybelsus only works if you take it exactly the right way. The instructions on the label aren't suggestions.

1. Take in the morning, on an empty stomach, before any food, drink, or other oral medication.
2. Swallow whole with no more than 4 ounces (120 mL) of plain water. Larger water volumes wash the drug past the absorption window.
3. Wait at least 30 minutes before eating, drinking anything other than water, or taking other oral medications. Some prescribers recommend waiting 60 minutes for best absorption.
4. Do not split, crush, or chew the tablet.
5. Take at the same time each day. Consistency matters more for Rybelsus than for many other drugs.

If you eat too soon, drink other beverages, or take other medications within the 30-minute window, absorption drops to near zero. A patient who routinely takes Rybelsus with morning coffee or breakfast is essentially not taking the drug at all.

The strict timing is the single biggest reason patients fail on Rybelsus. Studies show real-world adherence is meaningfully lower than trial protocol adherence. If the timing rules are unworkable for your routine, an injectable GLP-1 is more forgiving.

Cost and insurance coverage in 2026

Rybelsus:

• Cash price: approximately $980 to $1,000 per month for 14 mg
• Manufacturer copay savings card: as low as $10 per month for eligible commercially insured patients
• Medicare Part D: variable coverage, often tier 3 with copays of $40 to $300
• Medicaid: covered in most states for type 2 diabetes

Pipeline drugs (after approval):

• Pricing not yet public
• Industry analysts expect orforglipron to be priced similarly to injectable GLP-1 medications, around $900 to $1,200 per month before insurance
• Once-daily oral pills typically have higher manufacturing margin than weekly peptide injections; final pricing depends on competitive positioning

If you're uninsured or your insurance doesn't cover oral semaglutide, the cash price is similar to injectable forms. The convenience benefit of an oral pill doesn't translate to a price advantage at the consumer level.

We cover GLP-1 cost in detail at /articles/cost-and-insurance/glp1-cost-without-insurance/.

FAQ

What's the only FDA-approved oral GLP-1 in 2026?

Rybelsus, which is oral semaglutide manufactured by Novo Nordisk. It comes in 3, 7, and 14 mg tablets and is FDA-approved for type 2 diabetes. Higher-dose oral semaglutide for obesity is in FDA review.

Is there an oral version of Ozempic?

Rybelsus is the oral form of semaglutide, the same active ingredient as Ozempic. It's a different brand and a different dose, but the drug is the same. Rybelsus is FDA-approved for diabetes; Ozempic is also FDA-approved for diabetes; Wegovy (injectable) is approved for obesity.

Is there an oral version of Mounjaro or Zepbound?

Not yet. Eli Lilly's tirzepatide is currently injectable only. The company is developing oral options including orforglipron, but orforglipron is a different molecule (a non-peptide GLP-1 agonist), not an oral version of tirzepatide.

When will orforglipron be approved?

Phase 3 trials are reading out in 2026. Eli Lilly has signaled an FDA filing as soon as the data supports it. Approval is plausibly late 2026 or 2027 if Phase 3 confirms Phase 2 results, although timelines for novel mechanisms can slip.

Is Rybelsus as effective as Ozempic?

For diabetes, similar but slightly lower A1C reduction at current doses. For weight loss, meaningfully less than injectable Wegovy. The main constraint is bioavailability under 1%, which limits how much drug actually reaches the bloodstream.

Why do I need to wait 30 minutes after taking Rybelsus?

The SNAC absorption enhancer creates a brief window for semaglutide to cross the stomach lining. Eating, drinking, or taking other medications during that window dilutes the effect and washes the drug downstream where it cannot be absorbed.

Can I crush a Rybelsus tablet if I have trouble swallowing?

No. Crushing or splitting destroys the tablet's controlled-release mechanism and the SNAC interaction. If you can't swallow whole tablets, ask your prescriber about an injectable GLP-1.

Are there any oral non-peptide GLP-1 drugs available?

Not yet. Orforglipron, danuglipron, and GSBR-1290 are the leading candidates, all in late-stage development. None are FDA-approved as of April 2026.

Is compounded oral semaglutide a thing?

Some compounding pharmacies offer oral semaglutide formulations, often as troches or sublingual drops. The bioavailability of these compounded forms has not been studied in published trials. Most clinicians consider them less reliable than Rybelsus or injectable semaglutide.

Will an oral GLP-1 work as well as injectable for weight loss?

At current approved doses, no. High-dose oral semaglutide (50 mg) and orforglipron (36 mg), both in pipeline review, may close the gap. For maximum weight loss in 2026, injectable forms remain more effective.

Can I switch from injectable Wegovy to Rybelsus?

You can, but expect lower weight loss effect and more strict daily routine. Rybelsus is approved for diabetes, not obesity. Insurance coverage for an oral switch may be limited if obesity is the indication. Discuss with your prescriber.

Why is oral GLP-1 so much less effective than injectable?

Bioavailability. Less than 1% of an oral semaglutide tablet reaches the bloodstream. The injectable delivers nearly 100%. The next generation of non-peptide oral drugs may close the bioavailability gap because small molecules absorb much better than peptides.

Related guides

• GLP-1 Drugs Oral List: Every FDA-Approved Pill, Compounded Alternative, and When Oral Formulations Actually Work Better Than Injections
• GLP-1 Agonist List of Drugs: The Complete Guide to Every FDA-Approved and Compounded Option in 2026
• Complete GLP-1 RA Drugs List: Every FDA-Approved and Compounded Option in 2026
• GLP-1 Agonist List of Drugs: The Complete Catalog of FDA-Approved and Compounded Medications (2026)
• The Complete List of GLP-1 Agonist Drugs: FDA-Approved, Compounded, and Discontinued Options Organized by Mechanism
• Are There Oral GLP-1 Drugs? The Complete Guide to Pill-Form GLP-1 Medications in 2026

Sources

1. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide. Diabetes Care. 2019;42:1724-1732.
2. Knop FK et al. Oral Semaglutide 25 mg and 50 mg Versus Placebo in Adults with Overweight or Obesity (OASIS-1). Lancet. 2023;402:705-719.
3. Frias JP et al. Efficacy and Safety of Once-Daily Oral Orforglipron in Type 2 Diabetes (Phase 2). N Engl J Med. 2023;389:514-526.
4. Saxena AR et al. Danuglipron, a Once-Daily Oral GLP-1 Receptor Agonist (Phase 2). JAMA Network Open. 2023;6:e2314493.
5. FDA prescribing information for Rybelsus (semaglutide tablets), current revision.
6. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
7. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
8. Pfizer R&D Day investor presentation, December 2023, on danuglipron and lotiglipron program updates.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Rybelsus, Ozempic, and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.